Joseph Tuscano
Clinical trials sponsored by Joseph Tuscano, explained in plain language.
-
New combo therapy aims to boost remission in tough lymphoma cases
Disease control Recruiting nowThis study tests whether adding the drug epcoritamab to standard chemotherapy and a stem cell transplant can improve outcomes for people with large B-cell lymphoma that has returned or not responded to prior treatment. About 25 adults will receive the combination therapy. The goa…
Phase: PHASE2 • Sponsor: Joseph Tuscano • Aim: Disease control
Last updated May 17, 2026 08:53 UTC
-
Double punch: experimental drug may boost CAR-T success in tough lymphoma
Disease control Recruiting nowThis study tests whether adding the drug odronextamab before and after standard CAR-T cell therapy can help people with a type of aggressive lymphoma (DLBCL) that has returned or not responded to prior treatments. About 34 adults who have already tried at least two other therapie…
Phase: PHASE2 • Sponsor: Joseph Tuscano • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
New hope for aggressive lymphoma: targeted therapy before chemo shows promise
Disease control Recruiting nowThis study tests a two-step treatment for people with a fast-growing type of lymphoma that is hard to treat. First, a targeted drug (loncastuximab tesirine) plus rituximab is given to attack cancer cells directly. Then, standard chemotherapy (DA-EPOCH-R) is used to kill remaining…
Phase: PHASE2 • Sponsor: Joseph Tuscano • Aim: Disease control
Last updated May 11, 2026 20:52 UTC